IRUS Total

Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: Part i - Analytical validation and clinical qualification

File Description SizeFormat 
s12968-018-0484-5.pdfPublished version1.03 MBAdobe PDFView/Open
Title: Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: Part i - Analytical validation and clinical qualification
Authors: Puntmann, VO
Valbuena, S
Hinojar, R
Petersen, SE
Greenwood, JP
Kramer, CM
Kwong, RY
McCann, GP
Berry, C
Nagel, E
Bluemke, D
Bremerich, J
Botnar, R
Bucciarelli-Ducci, C
Choudhury, RP
Dweck, M
Eitel, I
Ferrari, V
Friedrich, M
Hundley, G
Lombardi, M
Lopez Fernandez, T
Marwick, T
Narula, J
Neubauer, S
Patel, A
Pennell, D
Plein, S
Prasad, S
Rademakers, F
Raman, S
Sakuma, H
Sanz, J
Schulz-Menger, J
Simonetti, O
Swift, A
Taylor, AJ
Teixeira, T
Thiele, H
Ugander, M
Westenberg, JJ
Young, AA
Item Type: Journal Article
Abstract: Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen.
Issue Date: 20-Sep-2018
Date of Acceptance: 5-Aug-2018
URI: http://hdl.handle.net/10044/1/63972
DOI: https://dx.doi.org/10.1186/s12968-018-0484-5
ISSN: 1097-6647
Publisher: BioMed Central
Journal / Book Title: Journal of Cardiovascular Magnetic Resonance
Volume: 20
Issue: 1
Copyright Statement: © 2018 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: 1102 Cardiovascular Medicine And Haematology
Nuclear Medicine & Medical Imaging
Publication Status: Published
Article Number: 67
Online Publication Date: 2018-09-20
Appears in Collections:National Heart and Lung Institute